Ultimaster Drug Eluting Stent family (Terumo) first stent to receive the mention 1-month DAPT in the reimbursement conditions in France

December 8, 2022

Corporate

December 8, 2022 – Terumo's Ultimaster™ drug-eluting stent family has become the first coronary stent to receive the mention of 1-month dual antiplatelet therapy (DAPT) in its reimbursement conditions in France.

This recognition reflects the strong body of clinical evidence supporting the Ultimaster stent family's safety profile with shortened DAPT duration, potentially offering physicians greater flexibility in managing antiplatelet therapy for appropriate patients following stent implantation.

"This is a significant recognition of the extensive clinical evidence behind the Ultimaster platform," said a Terumo representative. "Shorter DAPT duration can be an important consideration for certain patients, and we are pleased that this evidence is now reflected in France's reimbursement framework."

The Ultimaster stent family continues to be supported by a robust portfolio of clinical studies evaluating its performance across a range of patient populations and treatment strategies.

About Terumo India

Terumo India is a fast-growing medical devices company that serves to advance access to high-quality Cardiac & Vascular, and other medical devices for patients and medical practitioners in India. Terumo India is part of Terumo Corporation, a global leader in medical technology with headquarters in Tokyo, Japan. Established in 1921 and with its 100 years of history, Terumo's starting point and unchanging corporate mission has been 'Contributing to Society through Healthcare'.

Terumo India was established in 2013 with headquarters in Gurgaon, NCR Delhi and has since grown to touch over 100,000 lives with an expanding field force & distribution network. Terumo India is Great Place to Work® certified and has also been recognized as one of India's Top 15 Workplaces™ in Pharmaceuticals, Healthcare and Biotech 2022. The company runs several acclaimed training & development programs, working closely with its customers and academic partners to contribute to the skilling requirements of India's healthcare system.

Media Contact

Terumo India Private Limited

About Terumo

Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of "Contributing to Society through Healthcare." Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions.

Media Contact

Corporate Communication Dept., Terumo Corporation

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.